CoMentis Company

AmCyte develops encapsulated proliferated human islets for transplantation into patients with diabetes. The company specializes in adult stem cell research to treat diabetes with islet replacement therapy.
Investors
Technology:
Stem Cell
Industry:
Regenerative medicine
Headquarters:
United States
Founded Date:
2004
Employees Number:
51-100
Funding Status:
Late Stage Venture
Investors Number:
14
Total Funding:
$107.5M
Last Funding Type:
Series E
Register and Claim Ownership